alnylam
A strategic leader at Alnylam responsible for building and scaling an integrated ecosystem of systems and processes that enable efficient delivery of RNAi therapeutics. The role focuses on operational excellence across clinical operations, data management, and program management, ensuring standardized, user-centric processes that support real-time decision-making.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
135% above the average for this role
Scientist, Statistical Genetics
Alnylam Pharmaceuticals
Sr. Program Director - Regulatory and Clinical Development
Akero Therapeutics
Senior Project Manager
Definium Therapeutics
Submit Your Resume for Future Opportunities at Alnylam's Norton Manufacturing Site
Alnylam Pharmaceuticals
Director, Pipeline Commercial Strategy - Immunology
AbbVie
Senior Engagement Manager - Pre-Sales - Philippines
SalesForce1 Inc